3 Non-AI Stocks to Buy: MRK, UPS, CVX

Merck agreed to acquire Cidara Therapeutics (CDTX) for $9.2 billion in cash ($221.50/share), roughly a 109% premium, bolstering its infectious-disease pipeline ahead of Keytruda patent pressures. UPS reported revenue down ~4% YoY (domestic revenue down ~3%) while volumes fell ~12%, but revenue per piece rose ~10% as management shifts toward higher-margin segments and targets $3.5 billion of expense reductions, prompting a buy rating and a ~7% dividend yield. Chevron posted a record quarter of ~4.1 million boe/d (+21% YoY), generated ~$7 billion of adjusted free cash flow, returned ~$6 billion to shareholders in the quarter (about $78 billion over three years), and plans $10–20 billion annual returns through 2030, supporting a ~4.3% yield and buy view.

Analysis

Market structure: Merck's $9.2B cash buy of Cidara (CDTX) tightens the market for late-stage infectious-disease platforms and sets a new bid benchmark (~109% premium) for similarly positioned biotech targets; incumbent vaccine/antiviral players face higher M&A valuation pressure while Big Pharma with weak oncology pipelines (MRK) gain optionality. UPS's shed-Amazon strategy signals a structural shift in parcel mix toward higher-yield B2B/healthcare lanes — expect revenue-per-piece uplifts to persist if volumes remain ~10–15% lower in e‑commerce while margins expand.

Risk assessment: Tail risks include clinical failure or narrower label for Merck's asset (regulatory reversal), a precipitous oil-price drop that erodes Chevron (CVX) cash returns, and labor/contract shocks at UPS that could derail cost saves. Immediate (days) market moves: CDTX/MRK reprice; short-term (weeks–months): UPS margin trajectory and Chevron cash-return cadence; long-term (years): Keytruda patent dynamics and MRK’s pipeline replacement. Hidden dependencies: Merck is buying platform optionality, not just a single product; CF Industries' dividend upside is hostage to natural-gas prices and ammonia spreads.

Trade implications: Favor high-conviction longs in cash-return energy (CVX) and defensive income (UPS) but size positions conservatively: CVX benefits from buybacks/dividends and production growth; UPS is a turnaround trade dependent on execution of $3.5B cost cuts. Avoid paying top-tier takeover multiples for late‑stage biotechs; use option structures to own upside in MRK without full downside exposure.

Contrarian angles: Consensus celebrates the deal premium but underestimates integration and label risk — MRK upside is binary and likely underpriced into short-term options vols; CDTX shareholders realized value, but the transaction raises takeover comps in biotech, compressing future deal IRRs. The market may be underestimating cyclical downside for fertilizer (CF) if natural-gas prices fall >30% year-over-year, which would reduce FCF and force capital-return reconsideration.

Key Decisions for Investors

• Establish a 2% portfolio long position in CVX within 2 weeks, target 20%+ total return over 3 years (4.3% yield + buyback-driven 10% FCF CAGR); hedge tail risk with 6–12 month put protection at ~10% OTM.
• Build a 1–2% long in UPS (UPS) to capture a ~7% yield and margin-reversion upside; enter via selling 8–10% OTM cash‑secured puts to collect premium and/or buy stock and sell 3‑month covered calls; exit or cut to 0.5% if revenue-per-piece falls sequentially two quarters.
• Add a hedge-lite exposure to MRK (1% long) using a 12‑month call spread (buy 12‑month ATM call, sell 30–40% OTM call) to participate in pipeline/roll‑up upside while capping capital at risk; reassess after next FDA/pipeline update within 6 months.
• Initiate a 1% long in WAB ahead of potential dividend raise and industrial cyclicality; enter via buy-and-hold or a 6–9 month call spread. If natural-gas prices drop >30% YoY or ammonia spreads compress by >20% within 6 months, reduce CF (CF) exposure — avoid initiating new CF positions until ammonia margin stabilizes for two consecutive quarters.